Menu

Criticism for Craig Venter’s “Face-Prediction” Software

The tool cannot predict a person’s face from DNA, say researchers—including some listed as coauthors on the publication. 

Sep 11, 2017
Catherine Offord

ISTOCK, SIMARIK

Update (September 12): Venter and his colleagues have published a response to Yaniv Erlich’s criticism of the paper. On bioRxiv, the authors refute Erlich’s claim that the paper contains “major flaws,” and call his approach to the data “misleading.” They also emphasize that their software can predict not only faces from DNA, but other phenotypic and demographic variables such as height and biological age.

A paper from Craig Venter and colleagues at his genetics company Human Longevity made waves after publication in PNAS last week (September 5) with its claim to be able to reconstruct a person’s face from his or her genome. Now, it’s attracting a tidal wave of criticism from researchers—including some who are listed as coauthors—with suggestions that the article is more self-serving for Venter’s private company than it is a scientific advance.

“Craig Venter cannot predict faces,” writes Yaniv Erlich, a computer scientist at Columbia University, in a post today (September 11) on figshare. To illustrate his point, Erlich, who has also penned a longer critique on bioRxiv, created a panel of faces: one of Craig Venter, another that the new software predicted using Venter’s genome, and a third of actor Bradley Cooper. “In short, many white males in the same angle would look like the predicted face,” he writes.

The company claims the software uses DNA to predict facial features, from skin color to cheekbone height. While the concept itself is not that far-fetched, the software does not come close achieving its goal, says Mark Shriver, an anthropologist at Pennsylvania State University who reviewed the paper for Science, where it was ultimately rejected. “Calling it predicting from the genome is what’s wrong,” he tells MIT Technology Review. “The main message is way overstated.”

One theory from critics is that the software relies mostly on race and sex to make predictions about average face types—a result backed up by the software’s poor performance on relatively homogeneous sets of data. From a set of 20 photographs of men and women of different races, the software picked out the correct face using DNA around 70 percent of the time. That rate dropped to 11 percent when only male European faces were included.

The paper argues on the basis of its results that access to DNA databases should be restricted for privacy reasons, raising a conflict of interest for a company that is building a giant genetic database, says study coauthor Jason Piper, who has since left Human Longevity to work at Apple. “I think genetic privacy is very important, but the approach being taken is the wrong one,” he tells Nature. “In order to get more information out of the genome, people have to share.”

A spokesperson for Human Longevity tells Nature that although the sample size of 1,061 people overall was small, the company stands by its methodology. What’s more, “the [Human Longevity] team is working on rebuttal to criticisms by Yaniv in BioRxiv.” 

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Getting More Consistent Results by Knowing the Quality of Your Protein
Getting More Consistent Results by Knowing the Quality of Your Protein
Download this guide from NanoTemper to learn how to identify and evaluate the quality of your protein samples!
Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
Increasing accuracy and reducing cost barriers, IDT’s innovative system delivers simple and cost-effective amplicon sequencing